Connection
Elizabeth Kessler to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Elizabeth Kessler has written about Antibodies, Monoclonal, Humanized.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.275 |
|
|
|
-
Augustin M, Laguerre B, Baldini C, Zedan AH, Gonzalez-Billalabeitia E, Fong PC, Zukov R, Hammerer P, Prentice M, Shore N, Necchi A, Todenhöfer T, Kessler ER, Kose F, Gurney H, Valderrama BP, Zhu P, Imai K, Liu Y, McDermott R. Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E. Eur Urol Oncol. 2026 Oct; 9(5):1039-1045.
Score: 0.151
-
Kessler ER, Callihan E, Hu J, Eule C, Srivastava G, Kemme DJ, Iruku P, Rana V, Moore J, Schuster SR, Amirault M, Flaig TW, Lam ET. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma. Cancer Res Commun. 2023 06; 3(6):1004-1012.
Score: 0.124
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|